Update of Brazilian guidelines for chronic heart failure - 2012;Atualização da diretriz Brasileira de insuficiência cardíaca crônica - 2012

Arquivos Brasileiros de Cardiologia

Volumn 98, Issue 1 SUPPL.1, 2012, Pages 1-33

  Bocchi, Edimar Alcides ^a   Marcondes Braga, Fabiana Goulart ^a   Bacal, Fernando ^a   Ferraz, Almir Sergio ^b   Albuquerque, Denilson ^c   de Almeida Rodrigues, Dirceu ^d   Mesquita, Evandro Tinoco ^e,f   Vilas Boas, Fábio ^g   Cruz, Fátima ^a   Ramires, Felix ^f   Villacorta, Humberto ^h   de Souza Neto, João David ^b   Neto, João Manoel Rossi ⁱ   Moura, Lídia Zytynski ^j   Beck da Silva, Luís ^a   Moreira, Luiz Felipe ^j   Rohde, Luis Eduardo Paim ^e   Montera, Marcelo Westerlund ^a   Simões, Marcus Vinicius ^k   da Consolação Moreira, Maria ^j   Clausell, Nadine ^l   Bestetti, Reinaldo ^c   Mourilhe Rocha, Ricardo ^a   Mangini, Sandrigo ^c   Rassi, Salvador ^m   Ayub Ferreira, Silvia Moreira ^a   Martins, Silvia Marinho ⁿ   Bordignon, Solange ^o   Issa, Victor Sarli ^a   more..

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^c STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e HOSPITAL PRÓ CARDÍACO   (Brazil)

^f FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^g HOSPITAL SANTA IZABEL   (Brazil)

^h Hospital de Messejana Dr Carlos Alberto Studart Gomes   (Brazil)

ⁱ PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^j HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^k FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^l HOSPITAL DE BASE   (Brazil)

^m Laboratório de Reprodução Humana   (Brazil)

ⁿ Real Hospital Portugues   (Brazil)

^o INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

more..

Author keywords

CDI; Diagnosis; Guidelines; Heart failure; Medical treatment; Prognosis; Review; Surgery; Surgical treatment; Treatment

Indexed keywords

ARTICLE; BRAZIL; HEART FAILURE; PRACTICE GUIDELINE;

EID: 84858265251     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/s0066-782x2012001000001     Document Type: Article

References (318)

1. Moutinho MA, Colucci FA, Alcoforado V, Tavares LR, Rachid MB, Rosa ML, et al. Heart failure with preserved ejection fraction and systolic dysfunction in the community. Arq Bras Cardiol. 2008;90(2):132-7.
2. Goldraich L, Clausell N, Biolo A, Beck-da-Silva L, Rohde LE. Preditores clínicos de fração de ejeção de ventrículo esquerdo preservada na insuficiência cardíaca descompensada. Arq Bras Cardiol. 2010;94(3):364-71.
3. Mangini S, Silveira FS, Silva C P, Grativvol PS, Seguro L F, Ferreira SM, et al. Decompensated heart failure in the emergency department of a cardiology hospital. Arq Bras Cardiol. 2008;90(6):400-6.
4. Rosa ML, Giro C, Alves T de O, Moura EC, Lacerda Lda S, Sant Anna L P, et al. Analysis of mortality and hospitalization for cardiovascular diseases in Niterói, between 1998 and 2007. Arq Bras Cardiol. 2011;96(6):477-83.
5. Nogueira PR, Rassi S, Corrêa Kde S. Epidemiological, clinical e therapeutic profile of heart failure in a tertiary hospital. Arq Bras Cardiol. 2010;95(3):392-8.
6. Santo AH. Chagas disease-related mortality trends, state of São Paulo, Brazil, 1985 to 2006: a study using multiple causes of death. Rev Panam Salud Publica. 2009;26(4):299-309.
7. Balieiro HM, Osugue RK, Rangel S P, Brandão R, Balieiro TL, Bernardez S, et al. Clinical and demographic profile and quality indicators for heart failure in a rural area. Arq Bras Cardiol. 2009;93(6):637-42.
8. Bocchi EA, Guimarães G, Tarasoutshi F, Spina G, Mangini S, Bacal F. Cardiomyopathy, adult valve disease and heart failure in South America. Heart. 2009;95(3):181-9.
9. Gaui EN, Klein CH, Oliveira GM. Mortality due to heart failure: extended analysis and temporal trend in three states of Brazil. Arq Bras Cardiol. 2010;94(1):55-61.
10. Bahrami H, Kronmal R, Bluemke DA, Olson J, Shea S, Liu K, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008;168(19):2138-45.
11. Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol. 2008;51(18):1775-83.
12. Butt AA, Chang CC, Kuller L, Goetz MB, Leaf D, Rimland D, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171(8):737-43.
13. Geiger S, Lange V, Suhl P, Heinemann V, Stemmler HJ. Anticancer therapy induced cardiotoxicity: review of the literature. Anticancer Drugs. 2010;21(6):578-90.
14. Strauss DG, Cardoso S, Lima JA, Rochitte CE, Wu KC. ECG scar quantification correlates with cardiac magnetic resonance scar size and prognostic factors in Chagas' disease. Heart. 2011;97(5):357-61.
15. Ribeiro AL, Rocha MO, Terranova P, Cesarano M, Nunes MD, Lombardi F. T-wave amplitude variability and the risk of death in Chagas disease. J Cardiovasc Electrophysiol. 2011;22(7):799-805.
16. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56(14):1071-8.
17. Tsutamoto T, Kawahara C, Nishiyama K, Yamaji M, Fujii M, Yamamoto T, et al. Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart failure. Am Heart J. 2010;159(1):63-7.
18. Velho FM, Cohen CR, Santos KG, Silvello D, Martinelli N, Biolo A, et al. Polymorphisms of matrix metalloproteinases in systolic heart failure: role on disease susceptibility, phenotypic characteristics, and prognosis. J Card Fail. 2011;17(2):115-21.
19. Kelder JC, Cowie MR, McDonagh TA, Hardman SM, Grobbee DE, Cost B, et al. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart. 2011;97:959-63.
20. Mant J, Al-Mohammad A, Swain S, Laramée P. Management of chronic heart failure in adults: synopsis of the National Institute for Health and clinical excellence guideline. Ann Intern Med. 2011;155(4):252-9.
21. Marinho FC, Vargas FS, Fabri J Jr, Acencio MM, Genofre EH, Antonangelo L, et al. Clinical usefulness of B-type natriuretic peptide in the diagnosis of pleural effusions due to heart failure. Respirology. 2011;16(3):495-9.
22. Moreira Mda C, Wang Y, Heringer-Walther S, Wessel N, Walther T. Prognostic value of natriuretic peptides in Chagas' disease: a head-to-head comparison of the 3 natriuretic peptides. Congest Heart Fail. 2009;15(2):75-81.
23. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley P F, Desvigne-Nickens P, et al. STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364(17):1617-25.
24. Taylor AJ, Cerqueira M, Hodgson JM, Mark D, Min J, O'Gara P, et al. ACCF/ SCCT/ACR/AHA/ASE/ASNC/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. Circulation. 2010;122(21):e525-55.
25. Guimarães G V, Carvalho VO, Bocchi EA. Reproducibility of the self-controlled six-minute walking test in heart failure patients. Clinics. 2008;63(2):201-6.
26. Rubim VS, Drumond Neto C, Romeo JL, Montera MW. Prognostic value of the Six-Minute Walk Test in heart failure. Arq Bras Cardiol. 2006;86(2):120-5.
27. Chandrashekhar Y, Anand IS. Can common exercise indices determine peak exercise oxygen consumption and anaerobic threshold during stress testing in patients with chronic congestive heart failure? Indian Heart J. 1993;45(6):493-5.
28. Carvalho VO, Bocchi EA, Guimarães GV. The carvedilol's beta-blockade in heart failure and exercise training's sympathetic blockade in healthy athletes during the rest and peak effort. Cardiovasc Ther. 2010;28(2):87-92.
29. Guimaraes GV, d'Avila VM, Silva MS, Ferreira SA, Ciolac EG, Carvalho VO, et al. A cutoff point for peak oxygen consumption in the prognosis of heart failure patients with beta-blocker therapy. Int J Cardiol. 2010;145(1):75-7.
30. Guimarães G V, Silva MS, d'Avila VM, Ferreira SM, Silva C P, Bocchi EA. Peak VO2 and VE/VCO2 slope in betablockers era in patients with heart failure: a Brazilian experience. Arq Bras Cardiol. 2008;91(1):39-48.
31. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided versus symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383-92.
32. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death) Trial. J Am Coll Cardiol. 2010;55(1):53-60.
33. Eurlings LW, van Pol PE, Kok WE, van Wijk S, van der Lodewijks Bolt C, Balk AH, et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results from the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56(25):2090-100.
34. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010:170(6):507-14.
35. Bowles KH, Holland DE, Horowitz DA. A comparison of in-person home care, home care with telephone contact and home care with telemonitoring for disease management. J Telemed Telecare. 2009;15(7):344-50.
36. Chaudhry SI, Mattera JA, Curtis J P, Spertus JA, Herrin J, Lin Z, et al. Telemonitoring in patients with heart failure. N Engl J Med. 2010;363(24):2301-9.
37. Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Böhm M, et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional. Circulation. 2011;123(17):1873-80.
38. Aguiar VB, Ochiai ME, Cardoso JN, Del Carlo CH, Morgado PC, Munhoz R T, et al. Relationship between depression, BNP levels and ventricular impairment in heart failure. Arq Bras Cardiol. 2010;95(6):732-7.
39. Cruz LN, Fleck M P, Polanczyk CA. Depression as a determinant of quality of life in patients with chronic disease: data from Brazil. Soc Psychiatry Psychiatr Epidemiol. 2010;45(10):953-61.
40. Dar O, Riley J, Chapman C, Dubrey SW, Morris S, Rosen SD, et al. A randomized trial of home telemonitoring in a typical elderly heart failure population in North West London: results of the Home-HF study. Eur J Heart Fail. 2009;11(3):319-25.
41. Anker SD, Koehler F, Abraham WT. Telemedicine and remote management of patients with heart failure. Lancet. 2011;378(9792):731-9.
42. Abraham WT, Adamson PB, Bourge RC, Aaron M F, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658-66.
43. Bourge RC, Abraham WT, Adamson PB, Aaron M F, Aranda Jr. JM, Magalski A, et al; COMPASS-HF Study Group. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol. 2008;51(11):1073-9.
44. Bocchi EA, Cruz F, Guimarães G, Pinho Moreira L F, Issa VS, Ayub Ferreira SM, et al. Long-term prospective, randomized, controlled study using repetitive education at six-month intervals and monitoring for adherence in heart failure outpatients: the REMADHE trial. Circ Heart Fail. 2008;1(2):115-24.
45. Sarabanda A V, Marin-Neto JA. Predictors of mortality in patients with Chagas' cardiomyopathy and ventricular tachycardia not treated with implantable cardioverter-defibrillators. Pacing Clin Electrophysiol. 2011;34(1):54-62.
46. Bertolino ND, Villafanha D F, Cardinalli-Neto A, Cordeiro JA, Arcanjo MJ, Theodoropoulos TA, et al. Prognostic impact of Chagas' disease in patients awaiting heart transplantation. J Heart Lung Transplant. 2010;29(4):449-53.
47. Nunes MC, Barbosa MM, Ribeiro AL, Colosimo EA, Rocha MO. Left atrial volume provides independent prognostic value in patients with Chagas cardiomyopathy. J Am Soc Echocardiogr. 2009;22(1):82-8.
48. Beck-da-Silva L, Goldraich L, Bonzanini L, Rossi G, Nuernberg G, Camey SA, et al. Pulse pressure and QRS width evaluation as an inexpensive tool for heart failure assessment. Congest Heart Fail. 2009;15(5):222-7.
49. Hershberger RE, Siegfried JD. Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 2011;57(16):1641-9.
50. Nakasato M, Strunk CM, Guimarães G, Rezende MV, Bocchi EA. Is the low-sodium diet actually indicated for all patients with stable heart failure? Arq Bras Cardiol. 2010;94(1):92-101.
51. Lennie TA, Song EK, Wu JR, Chung ML, Dunbar SB, Pressler SJ, et al. Three gram sodium intake is associated with longer event-free survival only in patients with advanced heart failure. J Card Fail. 2011;17(4):325-30.
52. Paterna S, Gaspare P, Fasullo S, Sarullo FM, Di Pasquale P. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin Sci (Lond). 2008;114(3):221-30.
53. Taylor RS, Ashton KE, Moxham T, Hooper L, Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane Review). Am J Hypertens. 2011;24(8):843-53.
54. Arcand J, Ivanov J, Sasson A, Floras V, Al-Hesayen A, Azevedo ER, et al. A high-sodium diet is associated with acute decompensated heart failure in ambulatory heart failure patients: a prospective follow-up study. Am J Clin Nutr. 2011;93(2):332-7.
55. Son YJ, Lee Y, Song EK. Adherence to a sodium-restricted diet is associated with lower symptom burden and longer cardiac event-free survival in patients with heart failure. J Clin Nurs. 2011;20(20-21):3029-38.
56. Martins Wde A, Ribeiro MD, Oliveira LB, Barros Lda S, Jorge AC, Santos CM, et al. Influenza and pneumococcal vaccination in heart failure: a little applied recommendation. Arq Bras Cardiol. 2011;96(3):240-5.
57. Vacina pneumocócica polivalente.[Acessado em 2011 jun 20] Disponível em: http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-ppv.pdf
58. Cruz FD, Issa VS, Ayub-Ferreira SM, Chizzola PR, Souza GE, Moreira L F, et al. Effect of a sequential education and monitoring programme on quality-of-life components in heart failure. Eur J Heart Fail. 2010;12(9):1009-15.
59. Domingues FB, Clausell N, Aliti GB, Dominguez DR, Rabelo ER. Education and telephone monitoring by nurses of patients with heart failure: randomized clinical trial. Arq Bras Cardiol. 2011;96(3):233-9.
60. Sauer J, Rabelo ER, Castro RA, Goldraich L, Rohde LE, Clausell N, et al. Nurses' performance in classifying heart failure patients based on physical exam: comparison with cardiologist's physical exam and levels of N-terminal pro-B-type natriuretic peptide. J Clin Nurs. 2010;19(23-24):3381-9.
61. Bento VF, Brofman PR. Impact of the nursing consultation on the frequency of hospitalizations in patients with heart failure in Curitiba, Parana State. Arq Bras Cardiol. 2009;92(6):454-60, 473-9, 490-6.
62. Roccaforte R, Demers C, Baldassarre F, Teo KK, Yusuf S. Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients: a meta-analysis. Eur J Heart Fail. 2005;7(7):1133-44.
63. Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) Investigators. Arch Intern Med. 2008;168(3):316-24.
64. Guimarães G V, Carvalho VO, Torlai V, Bocchi EA. Physical activity profile in heart failure patients from a Brazilian tertiary cardiology hospital. Cardiol J. 2010;17(2):143-5.
65. Piepoli M F, Conraads V, Corrà U, Dickstein K, Francis D P, Jaarsma T, et al. Exercise training in heart failure: from theory to practice: a consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Reahbilitation. Eur J Heart Fail. 2011;13(4):347-57.
66. Carvalho VO, Ciolac EG, Guimarães GV, Bocchi EA. Effect of exercise training on 24-hour ambulatory blood pressure monitoring in heart failure patients. Congest Heart Fail. 2009;15(4):176-80.
67. Pelegrino VM, Dantas RA, Ciol MA, Clark AM, Rossi LA, Simões MV. Health-related quality of life in Brazilian outpatients with Chagas and non-Chagas cardiomyopathy. Heart Lung. 2011;40(3):e25-31.
68. Lima MM, Rocha MO, Nunes MC, Sousa L, Costa HS, Alencar MC, et al. A randomized trial of the effects of exercise training in Chagas cardiomyopathy. Eur J Heart Fail. 2010;12(8):866-73.
69. Antunes-Correa LM, Kanamura BY, Melo RC, Nobre TS, Ueno LM, Franco FG, et al. Exercise training improves neurovascular control and functional capacity in heart failure patients regardless of age. Eur J Cardiovasc Prev Rehabil. 2011 Jun 22 [Epub ahead of print].
70. Ribeiro JP, Chiappa GR, Neder JA, Frankenstein L. Respiratory muscle function and exercise intolerance in heart failure. Curr Heart Fail Rep. 2009;6(2):95-101.
71. Stein R, Chiappa GR, Güths H, Dall'Ago P, Ribeiro JP. Inspiratory muscle training improves oxygen uptake efficiency slope in patients with chronic heart failure. J Cardiopulm Rehabil Prev. 2009;29(6):392-5.
72. Winkelmann ER, Chiappa GR, Lima CO, Viecili PR, Stein R, Ribeiro JP. Addition of inspiratory muscle training to aerobic training improves cardiorespiratory responses to exercise in patients with heart failure and inspiratory muscle weakness. Am Heart J. 2009;158(5):768.e1-e7.
73. Guimarães GV, Carvalho VO, Bocchi EA, d'Avila VM. Pilates in heart failure patients: a randomized controlled pilot trial. Cardiovasc Ther 2011 Jul 10 [Epub ahead of print].
74. Ciolac EG, Bocchi EA, Bortolotto LA, Carvalho VO, Greve JM, Guimarães GV. Effects of high-intensity aerobic interval training vs. moderate exercise on hemodynamic, metabolic and neuro-humoral abnormalities of young normotensive women at high familial risk for hypertension. Hypertens Res. 2010;33(8):836-43.
75. Ciolac EG, Bocchi EA, Greve JM, Guimarães GV. Heart rate response to exercise and cardiorespiratory fitness of young women at high familial risk for hypertension: effects of interval vs continuous training. Eur J Cardiovasc Prev Rehabil. 2011;18(6):824-30.
76. Silva MS, Bocchi EA, Guimaraes G V, Padovani CR, Silva MH, Pereira S F, et al. Benefits of exercise training in the treatment of heart failure: study with a control group. Arq Bras Cardiol. 2002;79(4):351-62.
77. Carvalho VO, Roque JM, Bocchi EA, Ciolac EG, Guimarães GV. Hemodynamic response in one session of strength exercise with and without electrostimulation in heart failure patients: a randomized controlled trial. Cardiol J. 2011;18(1):39-46.
78. Carvalho VO, Bocchi EA, Guimarães GV. Hydrotherapy in heart failure: a case report. Clinics (Sao Paulo). 2009;64(8):824-7.
79. Carvalho VO, Bocchi EA, Guimarães GV. The Borg scale as an important tool of self-monitoring and self-regulation of exercise prescription in heart failure patients during hydrotherapy: a randomized blinded controlled trial. Circ J. 2009;73(10):1871-6.
80. Pereira DA, Ribeiro-Samora GA, Vieira DS, Pereira LS, Coelho FM, Parreira VF, et al. Evaluation of the inflammatory response to two different intensities of exercise in individuals with heart failure. Inflammation. 2011 May 10 [Epub ahead of print].
81. Bocchi EA, Moura LZ, Issa VS, Cruz F, Carvalho VO, Guimarães GV. Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure. Cardiovasc Ther. 2011 Aug 3 [Epub ahead of print].
82. Guimarães GV, Belli JF, Bacal F, Bocchi EA. Behavior of central and peripheral chemoreflexes in heart failure. Arq Bras Cardiol. 2011;96(2):161-7.
83. Moura LZ, Guimarães GV, Pires PV, Cruz F, Stopa G, Bocchi EA. Exercise chemosensitivity in heart failure: ventilatory, chronotropic and neurohormonal responses. Arq Bras Cardiol. 2010;95(3):381-91.
84. Smart NA, Larsen AI, Le Maitre JP, Ferraz AS. Effect of exercise training on interleukin-6, tumour necrosis factor alpha and functional capacity in heart failure. Cardiol Res Pract. 2011;2011:532-620.
85. Piepoli M F, Davos C, Francis D P, Coats AJ. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328(7433):189.
86. O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al; ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439-50.
87. Kühr EM, Ribeiro RA, Rohde LE, Polanczyk CA. Cost-effectiveness of supervised exercise therapy in heart failure patients. Value Health. 2011;14(5 Suppl 1):S100-7.
88. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-85. Erratum in: Lancet. 2010;376(9757):1988.
89. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13.
90. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-7.
91. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-8.
92. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342(8885):1441-6.
93. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13.
94. Hjalmarson A, Waagstein F. COMET: a proposed mechanism of action to explain the results and concerns about dose. Lancet. 2003;362(9389):1077; author reply 1077-8.
95. Food and Drug Administration. January 11, 2010. Meeting of the Cardiovascular and Renal Drugs Advisory Committee.
96. Flather MD, Shibata MC, Coat AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-25.
97. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al; CIBIS Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112(16):2426-35.
98. Marques F, Castro RB, Nobre F, Pintya AO, Gallo Jr. L, Maciel BC, et al. Replacement of carvedilol for propranolol in patients with heart failure. Arq Bras Cardiol. 2010;95(1):107-14.
99. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385-90.
100. Pauschinger M, Rutschow S, Chandrasekharan K, Westermann D, Weitz A, Peter Schwimmbeck L, et al. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleuckin-1beta and MMP-8 expression and a modulated immune response. Eur J Heart Fail. 2005;7(4):444-52.
101. Sánchez-Más J, Turpín MC, Lax A, Ruipérez JA, Valdés Chávarri M, Pascual-Figal DA. Differential actions of eplerenone and spironolactone on the protective effect of testosterone against cardiomyocyte apoptosis in vitro. Rev Esp Cardiol. 2010;63(7):779-87.
102. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J. 2009;30(4):469-77.
103. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. EMPHASIS-HF Study Group. N Engl J Med. 2011;364(1):11-21.
104. Bocchi EA, Braga FG, Ferreira SM, Rohde LE, Oliveira WA, Almeida DR, et al. Sociedade Brasileira de Cardiologia. III Diretriz brasileira de insuficiência cardíaca crônica. Arq Bras Cardiol. 2009;93(1 supl.1):3-70.
105. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797-805.
106. Testani JM, Cappola TP, Brensinger CM, Shannon RP, Kimmel SF. Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol. 2011;58(4):375-82.
107. Mullens W, Abrahams Z, Francis GS, Sokos G, Starling RC, Young JB, et al. Usefulness of isosorbide dinitrate and hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol. 2009;103(8):1113-9.
108. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for prediciting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72.
109. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-100.
110. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New Engl J Med. 2009;361(12):1139-51.
111. Gage BF. Can we rely on RE-LY? N Engl J Med. 2009;361(12):1200-2.
112. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.
113. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.
114. Jesus PA, Neville I, Cincurá C, Menezes DF, Vieira-de-Melo RM, Lacerda AM, et al. Stroke history and Chagas disease are independent predictors of silent cerebral microembolism in patients with congestive heart failure. Cerebrovasc Dis. 2011;31(1):19-23.
115. Adamson PB, Gilbert EM. Reducing the risk of sudden death in heart failure with beta-blockers. J Card Fail. 2006;12(9):734-46.
116. Naccarelli GV, Lukas MA. Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. Clin Cardiol. 2005;28(4):165-73.
117. Brodine WN, Tung RT, Lee JK, Hockstad ES, Moss AJ, Zareba W, et al; MADIT-II Research Group. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol. 2005;96(5):691-5.
118. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al; Sudden Cardiac Death in Heart Failure Trial. (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-37.
119. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165-71.
120. Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine. J Gen Physiol. 2002;120(1):1-13.
121. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807-16.
122. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL Investigators. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30(19):2337-45.
123. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-85.
124. Dijkstra SC, Brouwer IA, van Rooij FJ, Hofman A, Witteman JC, Geleijnse JM. Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: the Rotterdam Study. Eur J Heart Fail. 2009;11(10):922-8.
125. Mozaffarian D, Bryson CL, Lemaitre RN, Burke GL, Siscovick DS. Fish intake and risk of incident heart failure. J Am Coll Cardiol. 2005;45(12):2015-21.
126. Yamagishi K, Iso H, Date C, Fukui M, Wakai K, Kikuchi S, et al; Japan Collaborative Cohort Study for Evaluation of Cancer Risk Study Group. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women. J Am Coll Cardiol. 2008;52(12):988-96.
127. Yamagishi K, Nettleton JA, Folsom AR. Plasma fatty acid composition and incident heart failure in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J. 2008;156(5):965-74.
128. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI Prevenzione trial Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354(9177):447-55.
129. Tavazzi L, Maggioni A P, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223-30.
130. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2011;57(7):870-9.
131. Zhao YT, Shao L, Teng LL, Hu B, Luo Y, Yu X, et al. Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure. J Int Med Res. 2009;37(6):1831-41.
132. Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes. 2006;55(4):924-8.
133. Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol. 2007;27(9):1918-25.
134. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96(9):939-49.
135. Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improved body weight in severe heart failure. J Heart Lung Transplant. 2006;25(7):834-8.
136. Freitas Jr. A F, Bacal F, Oliveira Jr Jde L, Santos RH, Moreira L F, Silva C P, et al. Impact of sublingual sildenafil on pulmonary hypertension in patients with heart failure. Arq Bras Cardiol. 2009;92(2):116-26.
137. Guimaraes GV, d'Avila VM, Pires P, Bacal F, Stolf N, Bocchi E. Acute effects of a single dose of phosphodiesterase type 5 inhibitor (sildenafil) on systemic arterial blood pressure during exercise and 24-hour ambulatory blood pressure monitoring in heart transplant recipients. Transplant Proc. 2007;39(10):3142-9.
138. Guazzi M. Sildenafil and phosphodiesterase-5 inhibitors for heart failure. Curr Heart Fail Rep. 2008;5(2):110-4.
139. Bocchi EA, Guimarães G, Mocelin A, Bacal F, Bellotti G, Ramires J F. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation. 2002;106(9):1097-103.
140. Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail. 2008;14(3):189-97.
141. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4(1):8-17.
142. Marazzi G, Gebara O, Vitale C, Caminiti G, Wajngarten M, Volterrani M, et al. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy. Adv Ther. 2009;26(4):455-61.
143. Gunes Y, Guntekin U, Tuncer M, Sahin M. Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels. 2009;24(4):277-82.
144. Belardinelli R, Lacalaprice F, Faccenda E, Volpe L. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil. 2008;15(5):533-40.
145. Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118(12):1250-8.
146. Belardinelli R, Cianci G, Gigli M, Mazzanti M, Lacalaprice F. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol. 2008;51(6):611-5.
147. Gunes Y, Guntekin U, Tuncer M, Sahin M. The effects of trimetazidine on heart rate variability in patients with heart failure. Arq Bras Cardiol. 2009;93(2):154-8.
148. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97(4):278-86.
149. Bocchi EA, Moreira L F, Bellotti G, Barreto AC, Azul LG, Stolf N, et al. Hemodynamic study during upright isotonic exercise before and six months after dynamic cardiomyoplasty for idiopathic dilated cardiomyopathy or Chagas' disease. Am J Cardiol. 1991;67(2):213-4.
150. Moreira LF, Stolf NA, de Lourdes Higuchi M, Bacal F, Bocchi EA, Oliveira SA. Current perspectives of partial left ventriculectomy in the treatment of dilated cardiomyopathy. Eur J Cardiothorac Surg. 2001;19(1):54-60.
151. Bocchi EA, Bellotti G, Moreira LF, Bacal F, de Moraes AV, Fiorelli A, et al. Mid-term results of heart transplantation, cardiomyoplasty, and medical treatment of refractory heart failure caused by idiopathic dilated cardiomyopathy. J Heart Lung Transplant. 1996;15(7):736-45.
152. Moreira L F, Benício A, Bacal F, Bocchi EA, Stolf NA, Oliveira SA. Determinants of long-term mortality of current palliative surgical treatment for dilated cardiomyopathy. Eur J Cardiothorac Surg. 2003;23(5):756-63.
153. Metzger M, Higuchi ML, Moreira LF, Chaves MJ, Castelli JB, Silvestre JM, et al. Relevance of apoptosis and cell proliferation for survival of patients with dilated cardiomyopathy undergoing partial left ventriculectomy. Eur J Clin Invest. 2002;32(6):394-9.
154. Bocchi EA. Cardiomyoplasty for treatment of heart failure. Eur J Heart Fail. 2001;3(4):403-6.
155. Parga JR, Avila L F, Bacal F, Moreira L F, Stolf NG, Ramires JA, et al. Partial left ventriculectomy in severe idiopathic dilated cardiomyopathy: assessment of short-term results and their impact on late survival by magnetic resonance imaging. J Magn Reson Imaging. 2001;13(5):781-6.
156. Bocchi EA, Bellotti G, Vilella de Moraes A, Bacal F, Moreira L F, Esteves-Filho A, et al. Clinical outcome after left ventricular surgical remodeling in patients with idiopathic dilated cardiomyopathy referred for heart transplantation: short-term results. Circulation. 1997;96(9 Suppl):II-165-71; discussion II-171-2.
157. Tamburino C, Ussia G P, Maisano F, Capodanno D, La Canna G, Scandura S, et al. Percutaneous mitral valve repair with the MitraClip system: acute results from a real world setting. Eur Heart J. 2010;31(11):1382-9.
158. Hovnanian AL, Matos Soeiro A, Serrano CV, Oliveira SA, Jatene FB, Stolf NA, et al. Surgical myocardial revascularization of patients with ischemic cardiomyopathy and severe left ventricular disfunction. Clinics. 2010;65(1):3-8.
159. Passamani E, Davis KB, Gillespie MJ, Killip T. A randomised trial of coronary artery bypass surgery: survival of patients with a low ejection fraction. N Engl J Med. 1985;312(26):1665-71.
160. Fernandes DR, Tsutsui JM, Bocchi EA, César LA, Sbano JC, Ramires JA, et al. Qualitative and quantitative real time myocardial contrast echocardiography for detecting hibernating myocardium. Echocardiography. 2011;28(3):342-9.
161. Kunadian V, Zaman A, Qiu W. Revascularization among patients with severe left ventricular dysfunction: a meta-analysis of observational studies. Eur J Heart Fail. 2011;13(7):773-84.
162. Cleland JG, Freemantle N, Ball SG, Bonser RS, Camici P, Chattopadhyay S, et al. The heart failure revascularization trial (HEART): rationale design and methodology. Eur J Heart Fail. 2003;5(3):295-303.
163. Cleland JG, Calvert M, Freemantle N, Arrow Y, Ball SG, Bonser RS, et al. The Heart Failure Revascularisation Trial (HEART). Eur J Heart Fail. 2011;13(2):227-33.
164. Cleland JGF, Freemantle N. Revascularization for patients with heart failure. Inconsistencies between theory and practice. Eur J Heart Fail. 2011;13(7):694-7.
165. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607-16.
166. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. STICH Trial Investigators. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364(17):1617-25.
167. Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, et al. STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360:1705-17.
168. Bacal F, Souza-Neto JD, Fiorelli AI, Mejia J, Marcodes-Braga FG, Mangini S, et al. Sociedade Brasileira de Cardiologia. II Diretriz brasileira de transplante cardiaco. Arq Bras Cardiol. 2009;94(1supl1):e16-e73.
169. Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann Thorac Surg. 2001;71(6):1833-8.
170. Bocchi EA, Fiorelli A; First Guideline Group for Heart Transplantation of the Brazilian Society of Cardiology. The Brazilian experience with heart transplantation: a multicenter report. J Heart Lung Transplant. 2001;20(6):637-45.
171. Bacal F, Veiga VC, Fiorelli A, Bellotti G, Bocchi EA, Stolf N, et al. Análise dos fatores de risco da doença vascular do enxerto em pacientes assintomáticos após transplante cardíaco. Arq Bras Cardiol. 2000;75(5):413-20.
172. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PE, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19):2388-442.
173. Bacal F, de Freitas Jr. AF, Moreira L F, Fiorelli AI, Mangini S, Abuhab A, et al. Validation of a cutoff value on echo Doppler analysis to replace right heart catheterization during pulmonary hypertension evaluation in heart transplant candidates. Transplant Proc. 2010;42(2):535-8.
174. Bocchi EA, Bellotti G, Uip D, Kalil J, de Lourdes Higuchi M, Fiorelli A, et al. Long-term follow-up after heart transplantation in Chagas' disease. Transplant Proc. 1993;25(1 Pt 2):1329-30.
175. Borghetti-Maio SA, Romano BW, Bocchi EA, Moreira L F, Barreto AC, Stolf NA, et al. Quality of life after cardiomyoplasty. J Heart Lung Transplant. 1994;13(2):271-5.
176. Fiorelli AI, Stolf NA, Honorato R, Bocchi E, Bacal F, Uip D, et al. Later evolution after cardiac transplantation in Chagas' disease. Transplant Proc. 2005;37(6):2793-8.
177. Bocchi EA, Higuchi ML, Vieira ML, Stolf N, Bellotti G, Fiorelli A, et al. Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease. J Heart Lung Transplant. 1998;17(4):399-405.
178. Campos S V, Strabelli TM, Amato Neto V, Silva C P, Bacal F, Bocchi EA, et al. Risk factors for Chagas' disease reactivation after heart transplantation. J Heart Lung Transplant. 2008;27(6):597-602.
179. Bacal F, Silva C P, Bocchi EA, Pires PV, Moreira L F, Issa VS, et al. Mychophenolate mofetil increased chagas disease reactivation in heart transplanted patients: comparison between two different protocols. Am J Transplant. 2005;5(8):2017-21.
180. Bocchi EA, Bellotti G, Mocelin AO, Uip D, Bacal F, Higuchi ML, et al. Heart transplantation for chronic Chagas' heart disease. Ann Thorac Surg. 1996;61(6):1727-33.
181. Bestetti RB, Souza TR, Lima M F, Theodoropoulos TA, Cordeiro JA, Burdmann EA. Effects of mycophenolate mofetil-based immunosuppressive regimen in Chagas heart transplant recipients. Transplantation. 2007;84(3):441-2.
182. Costanzo MR, Dipchard A, Starling R, Anderson A, Chan M, Desai S, et al. International Society of Heart and Lung Transplantation Guidelines for the care of heart transplants recipients. J Heart Lung Transplant. 2010;29(8):914-56.
183. Fiorelli AI, Santos RH, Oliveira Jr. JL, Bacal F, Bocchi EA, Lourenço DD, et al. Heart transplant in 107 cases of Chagas'disease. Transplant Proc. 2011;43(1):220-4.
184. Eckman PM, Hanna M, Taylor DO, Starling RC, Gonzalez-Stawinski GV. Management of sensitized adult heart transplant candidate. Clin Transplant. 2010;24(6):726-34.
185. Gude E, Anderssen AK, Arora S, Gullestad L, Grov I, Hartmann A. Acute renal failure early after heart transplantation: risk factors and clinical consequences. Clin Transplant. 2010:24(6):E207-13.
186. Bocchi EA, Vieira ML, Fiorelli A, Hayashida S, Mayzato M, Leirner A, et al. Hemodynamic and neurohormonal profile during assisted circulation with heterotopic artificial ventricle followed by heart transplantation. Arq Bras Cardiol. 1994;62(1):23-7.
187. Galantier J, Moreira L F, Benício A, Leirner AA, Cestari I, Bocchi EA, et al. Hemodynamic performance and inflammatory response during the use of VAD-InCor as a bridge to transplant. Arq Bras Cardiol. 2008;91(5):327-34.
188. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan D F, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-43.
189. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transpl. 2011;30(2):115-23.
190. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241-51.
191. Slaughter MS, Meyer AL, Birks EJ. Destination therapy with left ventricular assist devices: patient selection and outcomes. Curr Opin Cardiol. 2011;26(3):232-6.
192. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart failure events. N Engl J Med. 2009;361(14):1329-38.
193. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385-95.
194. Holzmeister J, Leclercq C. Implantable cardioverter defibrillators and cardiac resynchronisation therapy. Lancet. 2011;378(9792):722-30.
195. Neto NR, Fonseca GC, Torres GG, Pinheiro MA, Miranda GB. Correlation between electrocardiographic features and mechanical dyssynchrony in heart failure patients with left bundle branch block. Ann Noninvasive Electrocardiol. 2011;16(1):41-8.
196. Chung ES, Leon AR, Tavazzi L, Sun J P, Nihoyannopoulos P, Merlino J, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation. 2008;117(20):2608-16.
197. Wells G. Parkash R, Healey JS, Talajic M, Arnold JM, Sullivan S. et al. Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. CMAJ. 2011;183(4):421-9.
198. Bertoldi EG, Rohde LE, Zimerman LI, Pimentel M, Polanczyk CA. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income country's public health system. Int J Cardiol. 2011 Jun 23 [Epub ahead of print].
199. Duarte J de O, Magalhães L P, Santana OO, Silva LB, Simões M, Azevedo DO, et al. Prevalence and prognostic value of ventricular dyssynchrony in Chagas cardiomyopathy. Arq Bras Cardiol. 2011;96(4):300-6.
200. Martinelli Filho M, de Siqueira S F, Costa R, Greco OT, Moreira L F, D'avila A, et al. Conventional versus biventricular pacing in heart failure and bradyarrhythmia: the COMBAT study. J Card Fail. 2010;16(4):293-300.
201. De Keulenaer G W, Brutsaert DL. Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation. 2011;123(18):1996-2004.
202. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123(18):2006-2013.
203. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(20):2539-50.
204. Maeder TM, Kaye DM. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2009;53(11):905-18.
205. Heart Failure Society of America, Lindenfeld, J, Albert NM, Boehmer J P, Collins S P, Ezekowitz JA, Givertz MM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16(6):e1-194.
206. Reis FJ, Fernandes AM, Bitencourt AG, Neves FB, Kuwano AY, França VH, et al. Prevalence of anemia and renal insufficiency in non-hospitalized patients with heart failure. Arq Bras Cardiol. 2009;93(3):268-74.
207. Feola M, Lombardo E, Taglieri C, Piccolo S, Vado A. Plasma BNP and renal failure as prognostic factors of mid-term clinical outcome in congestive heart failure patients. Int J Cardiol. 2011;149(1):114-5.
208. Scrutinio D, Passantino A, Lagioia R, Santoro D, Cacciapaglia E. Detection and prognostic impact of renal dysfunction in patients with chronic heart failure and normal serum creatinine. Int J Cardiol. 2011;147(2):228-33.
209. Villacorta H, Saenz-Tello B F, Santos EB, Steffen R, Wiefels C, Lima LC, et al. Renal dysfunction and anemia in patients with heart failure with reduced versus normal ejection fraction. Arq Bras Cardiol. 2010;94(3):357-63.
210. Ferreira SM, Guimarães GV, Cruz FD, Issa VS, Bacal F, Souza GE, et al. Anemia and renal failure as predictors of risk in a mainly non-ischemic heart failure population. Int J Cardiol. 2010;141(2):198-200.
211. Miguel CE, Bortoluzzi TB, Otaviano A P, Cardinalli-Neto A, Faria da Rocha B, Ferrari SJ, et al. Prognostic significance of anemia in patients with chronic systolic heart failure secondary to Chagas' cardiomyopathy. Acta Trop. 2011;120(3):219-23.
212. Santos EB, Tello BS, Villacorta H, Sales AL, Wiefels C, Teixeira PS, et al. Anemia and heart failure in a community-based cohort: comparison with a specialized outpatient clinic. Arq Bras Cardiol. 2010;94(1):102-8.
213. Abraham WT, Anand IS, Klapholz M, Ponikowski P, Scarlata D, Wasserman SM, et al. Treatment of anemia with darbepoetin alfa in heart failure. Congest Heart Fail. 2010;16(3):87-95.
214. Kotecha D, Ngo K, Walters JA, Manzano L, Palazzuoli A, Flather MD. Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J. 2011;161(5):822e1-831e2.
215. Kao D P, Kreso E, Fonarow GC, Krantz MJ. Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000-2006). Am J Cardiol. 2011;107(1):69-73.
216. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-48.
217. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58(12):1241-51.
218. Lind M, Bounias I, Olsson M, Gudbjörnsdottir S, Svensson AM, Rosengren A. Glycaemic control and incidence of heart failure in 20 985 patients with type 1 diabetes: an observational study. Lancet. 2011;378(9786):140-6.
219. VanMelle J P, Bot M, de Jonge P, de Boer RA, van Veldhuisen DJ, Whooley MA. Diabetes, glycemic control, and new onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. 2010;33(9):2084-9.
220. Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31(7):824-31.
221. MacDonald MR, Eurich DT, Majumdar SR, Lewsey JD, Bhagra S, Jhund PS, et al. Treatment of Type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care. 2010;33(6):1213-8.
222. Evans JM, Doney AS, AlZadjali MA, Ogston SA, Petrie JR, Morris AD, et al. Effect of metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol. 2010;106(7):1006-10.
223. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail. 2010;16(3):200-6.
224. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009;54(5):422-8.
225. Issa VS, Amaral A F, Cruz FD, Ayub-Ferreira SM, Guimarães GV, Chizzola PR, et al. Glycemia and prognosis of patients with chronic heart failure--subanalysis of the Long-term Prospective Randomized Controlled Study Using Repetitive Education at Six-Month Intervals and Monitoring for Adherence in Heart Failure Outpatients (REMADHE) trial. Am Heart J. 2010;159(1):90-7.
226. Shimizu Y, Yamada S, Miyake F, Izumi T; PTMaTCH Collaborators. The effects of depression on the course of functional limitations in patients with chronic heart failure. J Card Fail. 2011;17(6):503-10.
227. Milani RV, Lavie CJ, Mehra MR, Ventura HO. Impact of exercise training and depression on survival in heart failure due to coronary heart disease. Am J Cardiol. 2011;107(1):64-8.
228. Frasure-Smith N, Lespérance F, Habra M, Talajic M, Khairy P, Dorian P, Roy D, et al; Atrial Fibrillation and Congestive Heart Failure Investigators. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. Circulation. 2009;120(2):134-40.
229. Pena FM, Modenesi Rde F, Piraciaba MC, Marins RM, Souza LB, Barcelos A F, et al. Prevalence and variables predictive of depressive symptoms in patients hospitalized for heart failure. Cardiol J. 2011;18(1):18-25.
230. O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al; SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56(9):692-9.
231. Jiang W, Krishnan R, Kuchibhatla M, Cuffe MS, Martsberger C, Arias RM, O'Connor CM; SADHART-CHF Investigators. Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). Am J Cardiol. 2011;107(4):545-51.
232. Fraguas R, da Silva Telles RM, Alves TC, Andrei AM, Rays J, Iosifescu D V, et al. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms. Contemp Clin Trials. 2009;30(3):205-11.
233. Singal P, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339(13):900-5.
234. Chen MH, Kerkelä R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008;118(1):84-95.
235. Felker G, Thompson R, Hare J, Hruban R, Clemetson D, Howard D, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077-84.
236. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol. 2010;7(10):564-75.
237. Kalil Filho R, Hajjar LA, Bacal F, Hoff PM, Diz Mdel P, Galas FR, et al. Sociedade Brasileira de Cardiologia. I Diretriz brasileira de cardio-oncologia. Arq Bras Cardiol. 2011;96(2 supl 1):1-52.
238. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2008;(2):CD003917.
239. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-62.
240. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474-81.
241. Wells QS, Lenihan DJ. Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected? Prog Cardiovasc Dis. 2010;53(2):140-8.
242. Kirova YM. Recent advances in breast cancer radiotherapy: Evolution or revolution, or how to decrease cardiac toxicity? World J Radiol. 2010;2(3):103-8.
243. Bestetti RB, Theodoropoulos TA, Cardinalli-Neto A, Cury PM. Treatment of chronic systolic heart failure secondary to Chagas heart disease in the current era of heart failure therapy. Am Heart J. 2008;156(3):422-30.
244. Bestetti RB, Dalbó C, Arruda CA, Correia Filho D, Freitas OC. Predictors of sudden cardiac death for patients with Chagas disease: a hospital-derived cohort study. Cardiology. 1996;87(6):481-7.
245. Bellabarba G, Davila D F, Torres A, Donis JH, Gonzalez JC, Figueroa O, et al. Plasma renin activity in chagasic patients with and without congestive heart failure. Int J Cardiol. 1994;47(1):5-9.
246. Bestetti RB, Coutinho-Netto J, Staibano L, Pinto LZ, Muccillo G, Oliveira JS. Peripheral and coronary sinus catecholamine levels in patients with severe congestive heart failure due to Chagas disease. Cardiology. 1995;86(3):202-6.
247. Bestetti RB, Otaviano AP, Cardinalli-Neto A, da Rocha BF, Theodoropoulos TA, Cordeiro JA. Effects of B-Blockers on outcome of patients with Chagas' cardiomyopathy with chronic heart failure. Int J Cardiol. 2011;151(2):205-8.
248. Theodoropoulos TA, Bestetti RB, Otaviano A P, Cordeiro JA, Rodrigues VC, Silva AC. Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy. Int J Cardiol. 2008;128(1):22-9.
249. Botoni FA, Poole-Wilson PA, Ribeiro AL, Okonko DO, Oliveira BM, Pinto AS, et al. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas' cardiomyopathy. Am Heart J. 2007;153(4):544-8
250. Issa VS, Amaral A F, Cruz FD, Ferreira SM, Guimarães G V, Chizzola PR, et al. Beta-blocker therapy and mortality of patients with Chagas' cardiomyopathy-a subanalysis of the REMADHE prospective trial. Circ Heart Fail. 2010;3(1):82-8.
251. Ramires FJA, Salemi VMC, Ianni BM, Fernandes F, Martins DG, Billate A, et al. Aldosterone antagonism in an inflammatory state: evidence for myocardial protection. J Renin Aniotensin Aldosterone Syst. 2006;7(3):162-7.
252. Ferrari SJ, Bestetti RB, Cardinalli-Neto A, Bortoluzzi TB. Digoxin serum levels in patients with Chagas' cardiomyopathy heart failure. Rev Soc Bras Med Trop. 2010;43(5):496-9.
253. Issa VS, Bocchi EA. Antitrypanosomal agents: treatment or threat? Lancet. 2010;376(9743):768-9.
254. Cardinalli-Neto A, Nakazone MA, Grassi LV, Tavares BG, Bestetti RB. Implantable cardioverter-defibrillator therapy for primary prevention of sudden cardiac death in patients with severe Chagas cardiomyopathy. Int J Cardiol. 2011;150(1):94-5.
255. Bestetti RB, Theodoropoulos TA. A systematic review of studies on heart transplantation for patients with end-stage Chagas' heart disease. J Card Fail. 2009;15(3):249-55.
256. Avila WS, Rossi EG, Ramires JA, Grinberg M, Bortolotto MR, Zugaib M, et al. Pregnancy in patients with heart disease: experience with 1,000 cases. Clin Cardiol. 2003;26(3):135-42.
257. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al; Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology ESC Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767-78.
258. Vettori D V, Rohde LE, Clausell N. Asymptomatic left ventricular dysfunction in puerperal women: an echocardiographic-based study. Int J Cardiol. 2011;149(3):353-7.
259. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121(13):1465-73.
260. Haykowsky MJ, Brubaker PH, John JM, Stewart K P, Morgan TM, Kitzman DW. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol. 2011;58(3):265-74.
261. Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Brockmeyer NH, et al. Prevalence of cardiac diastolic dysfunction in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials. 2010;11(3):156-62.
262. Butt AA, Chang CC, Kuller L, Goetz MB, Leaf D, Rimland D, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171(8):737-43.
263. Lewis W. Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS cardiomiopathy. Prog Cardiovasc Dis. 2003;45(4):305-18.
264. Charbit B, Gayat E, Voiriot P, Boccara F, Girard PM, Funck-Brentano C. Effects of HIV protease inhibitors on cardiac conduction velocity in unselected HIV-infected patients. Clin Pharmacol Ther. 2011;90(3):442-8.
265. Banerjee D, Haddad F, Zamanian R T, Nagendran J. Right ventricular failure: a novel era of targeted therapy. Curr Heart Fail Rep. 2010;7(4):202-11.
266. Guglin M, Verma S. Right side of heart failure. Heart Fail Rev. 2011 Jul 28. [Epub ahead of print].
267. Lahm T, McCaslin CA, Wozniak TC, Ghumman W, Fadl YY, Obeidat OS, et al. Medical and surgical treatment of acute right ventricular failure. J Am Coll Cardiol. 2010;56(18):1435-46.
268. Hefke T, Zittermann A, Fuchs U, Schulte-Eistrup S, Gummert J F, Schulz U. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation. Thorac Cardiovasc Surg. 2011 Mar 22. [Epub ahead of print]
269. Mikus E, Stepanenko A, Krabatsch T, Loforte A, Dandel M, Lehmkuhl HB, et al. Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur J Cardiothorac Surg. 2011;40(4):971-7.
270. Beyersdorf F, Schlensak C, Berchtold-Herz M, Trummer G. Regression of "fixed" pulmonary vascular resistance in heart transplant candidates after unloading with ventricular assist devices. J Thorac Cardiovasc Surg. 2010;140(4):747-9.
271. Calabrese F, Angelini A, Carturan E, Thiene G. Myocarditis and inflammatory cardiomyopathy: histomorphological diagnosis. Ernst Schering Res Found Workshop. 2006;(55):306-21.
272. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 2010;122(9):900-9.
273. Röttgen R, Christiani R, Freyhardt P, Gutberlet M, Schultheiss H P, Hamm B, et al. Magnetic resonance imaging findings in acute myocarditis and correlation with immunohistological parameters. Eur Radiol. 2011;21(6):1259-66.
274. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53(17):1475-87.
275. Gutberlet M, Spors B, Thoma T, Bertram H, Denecke T, Felix R, et al. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology. 2008;246(2):401-9.
276. Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109(10):1250-8.
277. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 2010;122(9):900-9.
278. Mahfoud F, Gärtner B, Kindermann M, Ukena C, Gadomski K, Klingel K, et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J. 2011;32(7):897-903.
279. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118(6):639-48.
280. Cooper Jr. LT, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC, et al. Giant cell myocarditis treatment trial investigators: usefulness of immunosupression for giant cell myocarditis. Am J Cardiol. 2008;102(11):1535-9.
281. Dennert R, Velthuis S, Schalla S, Eurlings L, van Suylen RJ, van Paassen P, et al. Intravenous immunoglobulin therapy for patients with idiopathic dilated cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther. 2010;15(2):193-201.
282. Frustaci A, Russo MA, Chimenti C. Randomized study on efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009;30(16):1995-2002.
283. Captur G, Nihoyannopoulos P. Left ventricular non-compaction: genetic heterogeneity, diagnosis and clinical course. Int J Cardiol. 2010;140(2):145-53.
284. Luedde M, Ehlermann P, Weichenhan D, Will R, Zeller R, Rupp S, et al. Severe familial left ventricular non-compaction cardiomyopathy due to a novel troponin T (TNNT2) mutation. Cardiovasc Res. 2010;86(3):452-60.
285. Martín M, Barriales V, Corros C, Santamarta E. Usefulness of cardiac magnetic resonance imaging in left ventricular non-compaction cardiomyopathy. Eur J Heart Fail. 2011;13(5):577.
286. Habib G, Charron P, Eicher JC, Giorgi R, Donal E, Laperche T, et al. Isolated left ventricular non-compaction in adults: clinical and echocardiographic features in 105 patients: results from a French registry. Eur J Heart Fail. 2011;13(2):177-85.
287. Whellan DJ, Ousdigian K T, Al-Khatib SM, Pu W, Sarkar S, Porter CB, et al; PARTNERS Study Investigators. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. J Am Coll Cardiol. 2010;55(17):1803-10.
288. Kamath SA, Drazner MH, Tasissa G, Rogers JG, Stevenson LW, Yancy CW. Correlation of impedance cardiography with invasive hemodynamic measurements in patients with advanced heart failure: the BioImpedance CardioGraphy (BIG) substudy of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) Trial. Am Heart J. 2009;158(2):217-23.
289. Nguyen CT, Aaronson A, Morrissey RP, Agarwal M, Willix RD, Schwarz ER. Myths and truths of growth hormone and testosterone therapy in heart failure. Expert Rev Cardiovasc Ther. 2011;9(6):711-20.
290. Bocchi E, Moura L, Guimarães G, Conceição Souza GE, Ramires JA. Beneficial effects of high doses of growth hormone in the introduction and optimization of medical treatment in decompensated congestive heart failure. Int J Cardiol. 2006;110(3):313-7.
291. Rosner MH, Ronco C. Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism. Congest Heart Fail. 2010;16(Suppl 1):S7-14.
292. Guglin M, Khan H. Pulmonary hypertension in heart failure. J Card Fail. 2010;16(6):461-74.
293. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, et al; Protect Steering Committee, Investigators, and Coordinators. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail. 2008;14(8):631-40.
294. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, et al; PROTECT Investigators and Committees. Rolofylline, an adenosine A1-Receptor antagonist, in acute heart failure. N Engl J Med. 2010;363(15):1419-28.
295. Voors AA, Dittrich HC, Massie BM, DeLucca P, Mansoor GA, Metra M, et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol. 2011;57(19):1899-907.
296. Abraham WT. Results of the TRIDENT-1 trial: a phase 2b study to assess the safety and tolerability of IV tonapofylline in subjects with acute decompensated heart failure and renal insufficiency. Paper presented at: the European Society of Cardiology Heart Failure Congress, Late Breaking Clinical Trials; May 30, 2010; Berlin, Germany.
297. Torp-Pedersen C, Kober L, Carlsen JE, Akkan D, Bruun NE, Dacoronias D, et al. A randomized trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail. 2008;10(1):89-95.
298. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary stem cell transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail. 2010;12(7):721-9.
299. Vilas-Boas F, Feitosa GS, Soares MB, Pinho-Filho JA, Mota AC, Almeida AJ, et al. Bone marrow cell transplantation in chagas' disease heart failure: report of the first human experience. Arq Bras Cardiol. 2011;96(4):325-31.
300. Bocchi EA, Bacal F, Guimarães G, Mendroni A, Mocelin A, Filho AE, et al. Granulocyte-colony stimulating factor or granulocyte-colony stimulating factor associated to stem cell intracoronary infusion effects in non ischemic refractory heart failure. Int J Cardiol. 2010;138(1):94-7.
301. Carvalho ACC. Terapia celular no Brasil. In: IV Simpósio Internacional Terapias Avançadas & Células-Tronco. Recife; 8 a 10 de Outubro; 2009.
302. Barbosa da Fonseca LM, Xavier SS, Rosado de Castro PH, Lima RS, Gutfilen B, Goldenberg RC, et al. Biodistribution of bone marrow mononuclear cells in chronic chagasic cardiomyopathy after intracoronary injection. Int J Cardiol. 2011;149(3):310-4.
303. Carvalho VO, Ruiz MA, Bocchi EA, Carvalho VO, Guimarães GV. Correlation between CD34+ and exercise capacity, functional class, quality of life and norepinephrine in heart failure patients. Cardiol J. 2009;16(5):426-31.
304. Baldo M P, Rodrigues SL, Mill JG. Granulocyte colony-stimulating factor for ischemic heart failure: should we use it? Heart Fail Rev. 2010;15(6):613-23.
305. Grossman J, Frishman WH. Relaxin: a new approach for the treatment of acute congestive heart failure. Cardiol Rev. 2010;18(6):305-12.
306. Lima MV, Ochiai ME, Cardoso JN, Morgado PC, Munhoz RT, Barretto AC. Hyperkalemia during spironolactone use in patients with decompensated heart failure. Arq Bras Cardiol. 2008;91(3):177-82, 194-9.
307. Pitt B, Anker SD, Bushinsky DA, Kitzman D W, Zannad F, Huang IZ; PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) Trial. Eur Heart J. 2011;32(7):820-8.
308. Malik FI, Hartman JJ, Elias KA, Morgan B P, Rodriguez H, Brejc K, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331(6023):1439-43.
309. Morgan B P, Muci A, Lu P P, Qian X, Tochimoto T, Smith WW, et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin. ACS Med Chem Lett. 2010;1(9):472-7.
310. Teerlink JR, Clarke C P, Saikali K, Lee JH, Chen MM, Escandon RD, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011;378(9792):667-75.
311. Cleland JGF, Teerlink JR, Senior R, Nifontov EN, McMurray JV, Lang CC, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011;378(9792):676-83.
312. Pêgo-Fernandes PM, Moreira L F, Souza GE, Bacal F, Bocchi EA, Stolf NA, et al. Endoscopic left sympathetic blockade in the treatment for dilated cardiomyopathy. Arq Bras Cardiol. 2010;95(6):685-90.
313. Sabbah HN, Gupta RC, Imai M, Irwin ED, Rastogi S, Rossing MA, et al. Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail. 2011;4(1):65-70.
314. De Ferrari GM, Crijns HJ, Borggrefe M, Milasinovic G, Smid J, Zabel M, et al; CardioFit Multicenter Trial Investigators. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J. 2011;32(7):847-55.
315. McMurray JJ, Pitt B, Latini R, Maggioni A P, Solomon SD, Keefe DL, et al; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1(1):17-24.
316. Solomon SD, Shin SH, Shah A, Skali H, Desai A, Kober L, et al; Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011;32(10):1227-34.
317. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401-14.
318. Gheorghiade M, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, et al; HORIZON-HF Investigators. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008;51(23):2276-85.